TrialMultiple sclerosis (Houndmills, Basingstoke, England)2022
Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial.
Bruce Ac Cree et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
26 papers cite it
this paperpooled ittrialcites it